TILs are also widely recognized as a potential biomarker and are generally associated with favorable prognosis; however, only a subset of CD8+ TILs can recognize tumor-specific neoantigens, contributing to heterogeneous clinical responses (182, 187). Here, CD8A is linked to neoplasm.